Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis

Fundamental and Clinical Pharmacology

Volumn 14, Issue 4, 2000, Pages 415-421

  Belfayol Pisanté, Laurence ^a   Guillevin, Loic ^b   Tod, Michel ^b   Fauvelle, Francis ^a  

^a Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

4 hydroxycyclophosphamide; Cyclophosphamide; Pharmacokinetics; Vasculitis

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALDOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; DRUG METABOLITE; MESNA; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE ACETATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTEMIC VASCULITIS;

EID: 0033812156     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2000.tb00424.x     Document Type: Article

References (29)

1. Classification and management of necrotising vasculitides
2. Optimisation of cyclophosphamide therapy in systemic vasculitis
3. Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis
4. Prediction of creatinine clearance from serum creatinine
5. Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide
6. High-performance liquid chomatographic measurement of cyclophosphamide in serum
7. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chomatography with solid-phase extraction
8. Measurement of 4-hydroxycyclophosphamide in serum by reversed-phase high-performance liquid chomatography
9. Clinical pharmacokinetics of cyclophosphamide
10. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation
11. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxy-cyclophosphamide in human marrow transplantation patients
12. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin and 4-hydroxycyclophosphamide regimen in breast cancer patients
13. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial
14. Variability in the pharmacokinetics of cyclophosphamide, methotrexate, and 5-fluorouracil in women receiving adjuvant treatment for breast cancer
15. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508
16. Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy
17. Dose escalation of cyclophosphamide in patients with breast cancer consequences for pharmacokinetics and metabolism
18. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in rat
19. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
20. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
21. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
22. Pharmacokinetic optimisation of anticancer therapy
23. Cyclophosphamide pharmacokinetics correlation with cardiac toxicity and tumour response
24. Clinical pharmacology of cyclophosphamide
25. The biotransformation of cyclophosphamide in man: Influence of prednisone
26. Rapid development of enhanced clearance after high-dose cyclophosphamide
27. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites
28. The disposition of cyclophosphamide in a group of myeloma patients
29. Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites